Vimarsana
Biggest News Aggregation in the World

Alembic News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Alembic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Alembic Today - Breaking & Trending Today

The penicillin war: India's journey from self-sufficiency to dependence on China - Vimarsana News

The penicillin war: India's journey from self-sufficiency to dependence on China

After India lost its dominance in making penicillin, a drought of three decades is coming to an end. The drug – which forms the base for a raft of extremely potent antibiotics – is part of the governments aggressive push for self-sufficiency in critical areas. Will the plan to claw back to the glorious past work?

Pricey Nvidia AI processors weigh on cash-strapped startups | Technology - Vimarsana News

Pricey Nvidia AI processors weigh on cash-strapped startups | Technology

With the chipmaker dominating the AI processor market, startups in the sector are raising more money and devoting increasing portions of it to hardware — leaving less for everything else.

Nvidia's pricey AI processors weigh on startups | Technology - Vimarsana News

Nvidia's pricey AI processors weigh on startups | Technology

With the chipmaker dominating the AI processor market, startups in the sector are raising more money and devoting increasing portions of it to hardware — leaving less for everything else.

Film mogul Jeffrey Katzenberg backs San Francisco AI startup | Technology - Vimarsana News

Film mogul Jeffrey Katzenberg backs San Francisco AI startup | Technology

Sales software maker Alembic to double staff in San Francisco after raising $14M. The startup has designed an AI system that analyzes data to predict the return on investment of marketing messages.

Alembic Pharma gears up for multiple product launches in coming quarters - Vimarsana News

Alembic Pharma gears up for multiple product launches in coming quarters

The Vadodra-based pharma manufacturer does not foresee additional capital expenditure for these initiatives but is shifting its strategic focus on new generation drugs over legacy products